KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) Research & Development (2019 - 2025)

LifeMD's Research & Development history spans 7 years, with the latest figure at -$920045.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 276.07% year-over-year to -$920045.0; the TTM value through Dec 2025 reached $7.3 million, up 7.13%, while the annual FY2025 figure was $7.3 million, 7.13% up from the prior year.
  • Research & Development reached -$920045.0 in Q4 2025 per LFMD's latest filing, down from $2.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.8 million in Q3 2025 to a low of -$920045.0 in Q4 2025.
  • Average Research & Development over 5 years is $1.2 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 541.23% in 2022, then tumbled 276.07% in 2025.
  • A 5-year view of Research & Development shows it stood at $216979.0 in 2021, then skyrocketed by 369.71% to $1.0 million in 2022, then surged by 96.04% to $2.0 million in 2023, then tumbled by 112.24% to -$244650.0 in 2024, then crashed by 276.07% to -$920045.0 in 2025.
  • Per Business Quant, the three most recent readings for LFMD's Research & Development are -$920045.0 (Q4 2025), $2.8 million (Q3 2025), and $2.7 million (Q2 2025).